Clinical Trial Update: Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating lenalidomide and dexamethasone with or without daratumumab in patients with high-risk smoldering multiple myeloma. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Decadron (Dexamethasone)
• Revlimid (lenalidomide)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Smoldering Plasma Cell Myeloma | Phase 3 | Status: RECRUITING